Search

Your search keyword '"Tomoda T"' showing total 521 results
Start Over Author "Tomoda T"
521 results on '"Tomoda T"'

1. Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab

Author

Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Miura A, Komori H, Kuroiwa K, Seki N, Fujimoto N, and Nakamura M

Subjects
urothelial carcinoma, pembrolizumab, immune-related adverse events, relative eosinophil count, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Mirii Harada,2 Shingo Tamura,7 Akihiro Miura,1 Hiroki Komori,1 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonobu Nakamura1 1Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 2Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; 3Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; 4Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; 5Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan; 6Department of Urology, Oita Prefectural Hospital, Oita, Japan; 7Department of Medical Oncology, National Hospital Organization Kyushu Medical Center, Fukuoka, JapanCorrespondence: Nobuki Furubayashi, Department of Urology, National Hospital Organization Kyushu Cancer Center, Notame 3-1-1, Minami-ku, Fukuoka, 811-1395, Japan, Tel +81-92-541-3231, Fax +81-92-551-4585, Email nobumduro@gmail.comBackground: To evaluate the association between immune-related adverse events (irAEs) and the clinical outcomes and also between irAEs and the post-treatment changes in the relative eosinophil count (REC) in advanced urothelial carcinoma (UC) patients treated with pembrolizumab.Materials and Methods: This retrospective study analyzed 105 advanced UC patients treated with pembrolizumab after disease progression on platinum-based chemotherapy between January 2018 and June 2021. The association between the occurrence of irAEs and the efficacy of pembrolizumab was investigated. The change in the REC from before the initiation of pembrolizumab therapy, to three weeks after treatment and the incidence of irAEs were determined.Results: Overall irAEs were associated with a significantly higher objective response rate (ORR) (58.8% vs 25.4%, P< 0.001), a longer progression-free survival (PFS) (25.1 months vs 3.1 months, P< 0.001) and overall survival (OS) (31.2 months vs 11.5 months, P< 0.001) compared to patients without irAEs; however, grade ≥ 3 irAEs were not associated with the ORR (36.4% vs 36.2%, P=0.989), PFS (9.5 vs 5.5 months, P=0.249), or OS (not reached vs 13.7 months, P=0.335). Compared to a decreased REC at 3 weeks after pembrolizumab, an increased relative REC at 3 weeks was not associated with the incidence of any-grade irAEs (32.3% vs 32.5%, P=0.984) or of grade ≥ 3 irAEs (10.8% vs 10.0%, P=0.900). Multivariate analyses revealed a female sex (P=0.005), Eastern Cooperative Oncology Group Performance Status ≥ 1 (P=0.024), albumin < 3.7 g/dl (P< 0.001), decreased REC (3 weeks later) (P< 0.001), and the absence of irAEs of any grade (P=0.002) to be independently associated with a worse OS.Conclusion: Patients with irAEs showed a significantly better survival compared to patients without irAEs in advanced UC treated with pembrolizumab. An increased posttreatment REC may be a marker predicting improved clinical outcomes and it had no significant relationship with the incidence of irAEs.Keywords: urothelial carcinoma, pembrolizumab, immune-related adverse events, relative eosinophil count

Published
2022

2. The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab

Author

Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Fujimoto N, and Nakamura M

Subjects
urothelial carcinoma pembrolizumab eosinophil neutrophil-to-eosinophil ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Shingo Tamura,7 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonobu Nakamura1 1Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 2Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; 3Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; 4Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; 5Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan; 6Department of Urology, Oita Prefectural Hospital, Oita, Japan; 7Department of Medical Oncology, National Hospital Organization Kyushu Medical Center, Fukuoka, JapanCorrespondence: Nobuki FurubayashiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Notame 3-1-1, Minami-ku, Fukuoka, 811-1395, JapanTel +81-92-541-3231Fax +81-92-551-4585Email nobumduro@gmail.comBackground: To evaluate the association of clinical outcomes with posttreatment changes in the relative eosinophil count (REC) and neutrophil-to-eosinophil ratio (NER) in patients with advanced urothelial cancer (UC) treated with pembrolizumab.Materials and Methods: We retrospectively analyzed 105 patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy. The REC and NER before and three weeks after pembrolizumab were recorded. A receiver operating characteristic curve was used to determine the optimal cut-off values for analyzing the risk.Results: There were no significant differences in the overall survival (OS) between the REC ≥ 4.8% and < 4.8% groups and the NER ≥ 13.7 and < 13.7 groups before pembrolizumab (p=0.997 and 0.669, respectively). However, a significant difference in the OS was confirmed between the increased and decreased REC groups and between the decreased and increased NER groups at 3 weeks after pembrolizumab (p< 0.001 and 0.002, respectively). Multivariate analyses revealed that an Eastern Cooperative Oncology Group Performance Status ≥ 2 (P=0.003), albumin < 3.7 g/dl (p=0.002), LDH > 246 U/L (p=0.011), disease site ≥ 3 organs (p=0.019), decreased posttreatment REC (3 weeks later) (p=0.002) and increased posttreatment NER (3 weeks later) (p=0.022) were independent prognostic factors for a worse OS.Conclusion: An increased REC and decreased NER after pembrolizumab may be significant early predictive markers of improved clinical outcomes in patients with advanced UC receiving pembrolizumab.Keywords: urothelial carcinoma, pembrolizumab, eosinophil, neutrophil-to-eosinophil ratio

Published
2021

3. Corrosion Protection Method with Sacrificial Anode for Steel Members in Boundary with Ground Using Water Swelling Rubber

Author

Xu, J., Kainuma, S., Takaki, K., Yang, M., Tomoda, T., Chaari, Fakher, Series Editor, Gherardini, Francesco, Series Editor, Ivanov, Vitalii, Series Editor, Cavas-Martínez, Francisco, Editorial Board Member, di Mare, Francesca, Editorial Board Member, Haddar, Mohamed, Editorial Board Member, Kwon, Young W., Editorial Board Member, Trojanowska, Justyna, Editorial Board Member, and Agarwal, Ramesh K., editor

Published
2023
Full Text
View/download PDF

4. Sparse-view image reconstruction with total-variation minimization applied to sparsely sampled projection data from SiPM-based photon-counting CT

Author

Sato, D., primary, Arimoto, M., additional, Kotoku, J., additional, Kawashima, H., additional, Kobayashi, S., additional, Okumura, K., additional, Murakami, K., additional, Lucyana, F., additional, Tomoda, T., additional, Kataoka, J., additional, Sagisaka, M., additional, Terazawa, S., additional, and Shiota, S., additional

Published
2024
Full Text
View/download PDF

9. 0+ -> 2+ neutrinoless double beta decay triggered directly by the Majorana neutrino mass

Author

Tomoda, T.

Subjects
High Energy Physics - Phenomenology
Abstract

We treat 0+ -> 2+ neutrinoless double beta decays taking into account recoil corrections to the nuclear currents. The decay probability can be written as a quadratic form of the effective coupling constants of the right-handed leptonic currents and the effective neutrino mass. We calculate the nuclear matrix elements for the 0+ -> 2+ neutrinoless double beta decays of 76Ge and 100Mo, and demonstrate that the relative sensitivities of 0+ -> 2+ decays to the neutrino mass and the right-handed currents are comparable to those of 0+ -> 0+ decays., Comment: 10 pages, 1 Postscript figure, Latex, uses elsart.sty and epsfig.sty

Published
1999
Full Text
View/download PDF

10. Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy

Author

Furubayashi N, Negishi T, Sakamoto N, Shimokawa H, Morokuma F, Song Y, Hori Y, Tomoda T, Tokuda N, Seki N, Kuroiwa K, and Nakamura M

Subjects
tumor microenvironment, platinum-based chemotherapy, pembrolizumab, organ-specific response rate, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, urothelial carcinoma
Abstract

Nobuki Furubayashi,1 Takahito Negishi,1 Naotaka Sakamoto,2 Hozumi Shimokawa,3 Futoshi Morokuma,4 Yoohyun Song,5 Yoshifumi Hori,6 Toshihisa Tomoda,7 Noriaki Tokuda,4 Narihito Seki,5 Kentaro Kuroiwa,6 Motonobu Nakamura1 1Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 2Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; 3Department of Medical Oncology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; 4Department of Urology, Saga-ken Medical Centre Koseikan, Saga, Japan; 5Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; 6Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan; 7Department of Urology, Oita Prefectural Hospital, Oita, JapanCorrespondence: Nobuki FurubayashiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Notame 3-1-1, Minami-Ku, Fukuoka, 811-1395, JapanTel +81-92-541-3231Fax +81-92-551-4585Email nobumduro@gmail.comBackground: To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC).Materials and Methods: Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retrospectively analyzed. The objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1.Results: We analyzed 69 patients (male, n=51; median age, 71 years) with 226 metastases. The ORR was 23.2%. In total, 32, 31, 16, 14, 13 and 7 patients had measurable lung (OSSR 31.3%), lymph node (OSSR 29.0%), local recurrence (OSSR 12.5%), primary tumor organ (OSSR 7.1%), liver (OSSR 23.1%) and bone (OSSR 28.6%) disease, respectively. The median overall survival (OS) for pembrolizumab was 10.9 months (95% confidence interval, 5.9‑13.7 months). Regarding organ-specific OS, a Log rank test significant differences in OS were confirmed between patients with and without primary tumor organ disease (p=0.046) and liver metastasis (p< 0.001).Conclusion: Metastases and primary tumor organ disease showed different tumor responses to pembrolizumab. The most prominent tumor response was found in lung metastasis and the least response was found in primary organ sites. The mechanisms of these different responses were unclear and there does not appear to be a constant trend between tumor shrinkage and OS in tumor sites. Further studies are needed.Keywords: urothelial carcinoma, platinum-based chemotherapy, pembrolizumab, organ-specific response rate, tumor microenvironment

Published
2021

24. The transcriptome landscape associated with Disrupted-in-Schizophrenia-1 locus impairment in early development and adulthood

Author

Yang, K, Kondo, MA, Jaaro-Peled, H, Cash-Padgett, T, Kano, SI, Ishizuka, K, Pevsner, J, Tomoda, T, Sawa, A, Niwa, M, Yang, K, Kondo, MA, Jaaro-Peled, H, Cash-Padgett, T, Kano, SI, Ishizuka, K, Pevsner, J, Tomoda, T, Sawa, A, and Niwa, M

Abstract

DISC1 was originally expected to be a genetic risk factor for schizophrenia, but the genome wide association studies have not supported this idea. In contrast, neurobiological studies of DISC1 in cell and animal models have demonstrated that direct perturbation of DISC1 protein elicits neurobiological and behavioral abnormalities relevant to a wide range of psychiatric conditions, in particular psychosis. Thus, the utility of DISC1 as a biological lead for psychosis research is clear. In the present study, we aimed to capture changes in the molecular landscape in the prefrontal cortex upon perturbation of DISC1, using the Disc1 locus impairment (Disc1-LI) model in which the majority of Disc1 isoforms have been depleted, and to explore potential molecular mediators relevant to psychiatric conditions. We observed a robust change in gene expression profile elicited by Disc1-LI in which the stronger effects on molecular networks were observed in early stage compared with those in adulthood. Significant alterations were found in specific pathways relevant to psychiatric conditions, such as pathways of signaling by G protein-coupled receptor, neurotransmitter release cycle, and voltage gated potassium channels. The differentially expressed genes (DEGs) between Disc1-LI and wild-type mice are significantly enriched not only in neurons, but also in astrocytes and oligodendrocyte precursor cells. The brain-disorder-associated genes at the mRNA and protein levels rather than those at the genomic levels are enriched in the DEGs. Together, our present study supports the utility of Disc1-LI mice in biological research for psychiatric disorder-associated molecular networks.

Published
2019

31. General lectures (II)

Author

Karasawa, Y., Ōnuma, H., Suzuki, H., Okazaki, T., Yasui, A., Murakami, T., Furuya, K., Ohtsuki, M., Furuya, K., Ohtsuki, M., Sata, H., Kondo, T., Takada, H., Kawaguchi, K., Sai, S., Takeda, S., Kitagawa, M., Morooka, T., Shiraishi, T., Namiki, M., Kawauchi, H., Nakagawa, K., Kuramata, H., Yamaguchi, Y., Kabakino, T., Inokuchi, T., Wakisaka, J., Yamauchi, Y., Debuchi, T., Ogo, W., Yamasaki, C., Sigemori, M., Hashimoto, K., Shirozu, T., Kaibara, N., Inokuchi, K., Soejima, K., Hiyama, T., Wakita, M., Ikemoto, T., Hayasaka, H., Fukui, S., Takeda, T., Aoyama, N., Takada, Y., Saheki, Y., Yoshida, Y., Minagawa, K., Okuyama, T., Yamamitsu, S., Konishi, Y., Ishimatsu, N., Murai, S., Nukaga, A., Toyama, S., Watanabe, Y., Mizushima, N., Abe, M., Maruyama, K., Yoshino, K., Suzuki, T., Akisato, K., Kitajima, M., Tabata, T., Hashimoto, M., Tanaka, T., Nakagawa, Y., Ishii, Y., Inoue, M., Katayama, S., Nakano, Y., Fukuda, M., Takaki, M., Hyodo, H., Kobayashi, J., Nishikawa, H., Morimoto, K., Takagi, T., Sako, S., Tomoda, H., Soejima, K., Furusawa, M., Inokuchi, K., Sassa, R., Unuma, T., Iwase, T., Yoshioka, T., Kusakabe, M., Iio, M., Kobayashi, S., Kizu, M., Kasugai, T., Yoshida, K., Kembo, T., Yoshida, T., Suga, Y., Suguro, T., Kono, Y., Mitsui, S., Nagamachi, Y., Nakamura, T., Suto, H., Higuchi, T., Kobayashi, J., Onai, M., Isizuka, K., Takei, A., Simoda, M., Sekiguchi, T., Shichijo, K., Akashi, Y., Mori, K., Ogasawara, K., Tanaka, R., Yoshikawa, K., Takahashi, T., Ogata, T., Tanaka, S., Seito, T., Matsuda, H., Imajo, T., Moriyasu, K., Takata, Y., Kamei, H., Murai, H., Takemitsu, T., Kanemitsu, T., Ishii, M., Imaizumi, M., Kondo, T., Inada, M., Glass, G. B. J., Ebata, K., Yamanaka, N., Watanabe, S., Yoshida, Y., Mori, H., Tsukasa, S., Sato, H., Chuman, Y., Nakahara, N., Taniguchi, H., Ehira, S., Hori, M., Irisa, T., Yokoyama, H., Kunieda, T., Ogushi, Y., Kawakami, K., Kuroda, M., Kuroda, M., Sasaki, D., SŌma, S., Yanagiya, S., Munakata, A., Matsunaga, F., Abiko, M., Ohuchi, H., Tai, C., Kawashima, T., Oosawa, W., Asakura, H., Senba, H., Hatayama, T., Yukawa, K., Konishi, T., Miyata, M., Shimazu, H., Kinoshita, T., Nukada, K., Yamagishi, T., Harada, K., Nakano, S., Yoshioka, T., Sakai, T., Shindo, K., Fukushima, K., Odagiri, S., Tarao, K., Saito, Y., Ohara, K., Sasaki, S., Tomoda, T., Kaneda, N., Yamaguchi, H., Hayashi, T., Tanaka, T., Suzuki, J., Kofune, Y., Urase, A., Yamagata, A., Sugino, N., Hatano, M., Oshima, K., Tanabe, T., Ohto, M., Okuda, K., Mitani, E., Yamamoto, S., Kobayashi, K., Ono, T., Kamata, T., Mohri, S., Makiishi, H., Kitano, A., Suga, Y., Tatumi, S., Mizuno, S., Tsumori, K., Shimizu, T., Nomatsu, K., Hiratsuka, H., Ichinose, M., Asakura, H., Morishita, T., Morita, A., Matsuzaki, S., Oda, M., Kamegaya, K., Tuchiya, M., Sambe, K., Murakami, Y., Machii, A., Nitta, Y., Aiso, Y., Kitahara, N., Sato, M., Yoshizawa, Y., Hishinuma, Y., Nagasako, H., Nao, Y., Harada, H., Mishima, K., Yamagata, Y., Mandai, M., Kondo, Y., Uchida, Y., Takizawa, S., Kinoshita, S., Kurihara, T., Sakumoto, K., Okamoto, H., Sakurai, S., Ishitobi, S., Tanaka, H., Ishihara, K., Kuno, N., Kasugai, T., Aoki, I., Kizu, M., Nakano, S., Suzuki, T., Horiguchi, Y., Kitamura, K., Miwa, M., Okada, K., Takeda, T., Endo, Y., Tatsuta, M., Morii, T., Okuda, S., Tamura, H., Fukuda, K., Sato, K., Koizumi, K., Takebe, T., Yamagata, S., Noda, S., Toda, Y., Hayakawa, T., Nakajima, S., Hitokawa, S., Nakano, S., Suzuki, T., Takeda, T., Sawabu, N., Hirose, S., Takada, A., Takeuchi, J., Kuniyasu, Y., Kakehi, H., Uchiyama, G., Arimizu, N., Okuda, K., Ohto, M., Kuroda, T., Saishyo, H., Tanabe, T., Takashima, T., Shin, M., Akashi, M., Moriyama, T., Uchimura, M., Tsuchiya, R., Kakizaki, G., Noto, N., Oizumi, T., Soeno, T., Maeta, T., Saito, T., Naito, S., Saito, T., Shimizu, K., Nakajima, T., Tanaka, M., Kin, T., Sugiyama, S., Takayama, H., Tomono, T., Kamijo, N., Kimura, Y., Matsuo, T., Shimada, M., Terashima, B., Oda, M., Furuta, S., Kashiwabara, K., Oka, S., Sugiura, M., Karasawa, M., Ito, K., Takei, K., Ishihara, Y., Kuroda, A., Sato, N., Noro, T., Ishikawa, H., Tajima, Y., Hashihira, S., Nishii, T., Mori, R., Takeda, Y., Yamadori, T., Wakabayashi, A., Iwata, S., Shiraso, M., Tokutake, K., Sato, H., Matsuno, S., Haga, N., Saito, Y., Suda, Y., Sato, T., Kuroda, T., Tsunoda, T., Kamata, T., Kanno, H., Aneha, Y., Kikuchi, K., Abe, M., Imamura, K., Kondo, O., Yuki, Y., Omata, S., Okamoto, S., Nagahara, H., Motoyama, H., Watanabe, H., Maekawa, T., Miyakawa, T., Watanabe, Y., Anazawa, Y., Murakami, T., Motoyama, T., Kawamura, T., Kusaka, Y., Sugiura, M., Shima, F., Abe, S., Ichihara, S., Nomura, M., Ushiyama, T., Futagawa, S., Ishida, M., Obata, G., Sugiyama, Y., Suzuki, K., Abo, M., Takeuchi, M., Tann, E., Kimura, K., Iwaya, A., Takahashi, H., Ono, K., Inoue, J., Miyaishi, S., Sasaki, T., Kuroyanagi, Y., Sato, T., Kato, H., Kido, C., Hibino, K., Kishikawa, M., Takeuchi, T., Murate, H., Tanabe, A., Kozuka, M., Ito, M., Kato, N., Yazaki, Y., Goto, K., Miyaji, M., Suzuki, K., Ito, K., Yokoi, J., Endo, I., Kato, S., Miyazaki, M., Murayama, N., Kawamura, A., Ono, T., Ohto, M., Murohisa, B., Uchimura, M., Hirai, S., Akashi, M., Furukawa, M., Nakashima, G., Furuse, H., Tsuchiya, R., Fukuda, T., Hanyu, F., Sakakibara, N., Suzuki, H., Ide, H., Momma, K., Nagashima, H., Matsushiro, T., Suzuki, N., Saitoh, T., Nakamura, N., Takahashi, W., Maeta, T., Hatanaka, T., Kobayashi, N., Sato, T., Hagano, M., Furusawa, T., Osuga, T., Portman, O. W., Ogata, T., Tanaka, S., Takahashi, K., Kibayashi, H., Yamazaki, H., Komaki, K., Tanimura, H., Hikasa, Y., Ogawa, R., Nakagawa, H., Osada, M., Koizumi, H., Katayama, M., Sakamoto, H., Manome, T., Sesoko, M., Kobayashi, M., Komine, Y., Saito, Y., Watanabe, N., Okabe, Y., Ogino, M., Naruke, T., Hoshika, T., Miyano, T., Tsuneoka, K., Kitajima, S., Nakada, I., Sasamori, Y., Munakata, H., Tanaka, K., Oguro, H., Numata, T., Oh-Uti, K., Yoshida, Y., Goto, S., Yanagiya, S., Takashina, K., Matsunaga, F., Sasaki, G., Kimura, A., Sasagawa, T., Takahashi, G., Sugiyama, H., Iwaki, K., Okada, S., Koizumi, H., Iwasaki, M., Kawashima, Y., Kaneda, H., Takahashi, K., Honda, T., Ariga, K., Sa, Woo pak, Hozawa, H., Hiratsuka, H., Susuki, T., Kato, Y., Mizuno, T., Oya, H., Yoshino, S., and Hattori, T.

Published
1973
Full Text
View/download PDF

34. DISC1 regulates trafficking and processing of APP and Aβ generation

Author

Shahani, N, primary, Seshadri, S, additional, Jaaro-Peled, H, additional, Ishizuka, K, additional, Hirota-Tsuyada, Y, additional, Wang, Q, additional, Koga, M, additional, Sedlak, T W, additional, Korth, C, additional, Brandon, N J, additional, Kamiya, A, additional, Subramaniam, S, additional, Tomoda, T, additional, and Sawa, A, additional

Published
2014
Full Text
View/download PDF

44. Satisfaction with bispectral index monitoring of propofol-mediated sedation during endoscopic submucosal dissection: a prospective, randomized study

Author

Imagawa, A., primary, Fujiki, S., additional, Kawahara, Y., additional, Matsushita, H., additional, Ota, S., additional, Tomoda, T., additional, Morito, Y., additional, Sakakihara, I., additional, Fujimoto, T., additional, Taira, A., additional, Tsugeno, H., additional, Kawano, S., additional, Yagi, S., additional, and Takenaka, R., additional

Published
2008
Full Text
View/download PDF

46. Stimulatory effect of interleukin-1 beta on the interferon-gamma-dependent HLA-DR production

Author

Tomoda, T, Kurashige, T, and Taniguchi, T

Subjects
Immunoblotting, HLA-DR Antigens, Recombinant Proteins, Culture Media, HLA-B7 Antigen, Interferon-gamma, Leukemia, Myeloid, Tumor Cells, Cultured, Cytokines, Humans, Tetradecanoylphorbol Acetate, RNA, Messenger, Research Article, Interleukin-1
Abstract

Expression of major histocompatibility complex (MHC) class II genes is induced by interferon-gamma (IFN-gamma) in antigen-presenting cells. When human leukaemia THP-1 and PL-21 cells were pretreated with phorbol ester, IFN-gamma-dependent induction of MHC class II gene was markedly enhanced. To elucidate the mechanism of the phenomenon, we examined the effect of cytokines which were secreted from THP-1 cells by the treatment of phorbol ester. Among those cytokines, interleukin-1 beta (IL-1 beta) had a positive effect on IFN-gamma-dependent induction of MHC class II genes. In order to rule out the possibility that different clones of THP-1 cells respond independently to IFN-gamma or phorbol ester, we showed that all independent single clones expressed MHC class II and produced IL-1 beta by IFN-gamma or phorbol ester, respectively.

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results